Summit Partners Public Asset Management LLC Boosts Position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Summit Partners Public Asset Management LLC raised its holdings in Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) by 547.9% in the 3rd quarter, according to the company in its most recent filing with the SEC. The firm owned 138,118 shares of the biotechnology company's stock after acquiring an additional 116,800 shares during the quarter. Summit Partners Public Asset Management LLC owned approximately 0.14% of Sarepta Therapeutics worth $17,250,000 as of its most recent SEC filing.

Several other large investors have also recently modified their holdings of SRPT. Innealta Capital LLC acquired a new position in shares of Sarepta Therapeutics in the second quarter worth approximately $31,000. Huntington National Bank raised its holdings in Sarepta Therapeutics by 150.9% during the 3rd quarter. Huntington National Bank now owns 291 shares of the biotechnology company's stock worth $36,000 after purchasing an additional 175 shares during the last quarter. Nkcfo LLC acquired a new position in shares of Sarepta Therapeutics in the 2nd quarter worth approximately $43,000. Riggs Asset Managment Co. Inc. boosted its stake in shares of Sarepta Therapeutics by 33.3% in the 2nd quarter. Riggs Asset Managment Co. Inc. now owns 300 shares of the biotechnology company's stock valued at $47,000 after purchasing an additional 75 shares during the last quarter. Finally, UMB Bank n.a. increased its position in shares of Sarepta Therapeutics by 105.9% during the third quarter. UMB Bank n.a. now owns 383 shares of the biotechnology company's stock worth $48,000 after buying an additional 197 shares during the period. Institutional investors own 86.68% of the company's stock.

Sarepta Therapeutics Stock Performance

Shares of SRPT traded down $4.60 during trading hours on Friday, hitting $133.34. The company's stock had a trading volume of 777,534 shares, compared to its average volume of 1,246,366. The company has a market cap of $12.74 billion, a price-to-earnings ratio of 106.67 and a beta of 0.81. The company has a debt-to-equity ratio of 0.93, a current ratio of 3.84 and a quick ratio of 3.03. The business has a 50 day simple moving average of $122.37 and a two-hundred day simple moving average of $131.48. Sarepta Therapeutics, Inc. has a 52-week low of $78.67 and a 52-week high of $173.25.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on the stock. Raymond James restated an "outperform" rating and issued a $150.00 target price on shares of Sarepta Therapeutics in a report on Thursday, October 10th. Jefferies Financial Group initiated coverage on Sarepta Therapeutics in a report on Monday, October 21st. They set a "buy" rating and a $165.00 price target on the stock. William Blair upgraded Sarepta Therapeutics to a "strong-buy" rating in a research note on Friday, August 30th. Needham & Company LLC reduced their price target on shares of Sarepta Therapeutics from $205.00 to $202.00 and set a "buy" rating for the company in a research report on Wednesday. Finally, Evercore ISI cut their price target on Sarepta Therapeutics from $179.00 to $170.00 and set an "outperform" rating for the company in a research note on Thursday, November 7th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating, twenty have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average price target of $175.77.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.